Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Orthofix International (OFIX) Stock Price
News headlines about Orthofix International (NASDAQ:OFIX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orthofix International earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 46.663550086193 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- Global Bone Graft and Substitutes Market by Product Type Bone Grafts and Bone Graft Substitute (mynewsdesk.com)
- Bone Growth Stimulator Market : Opportunities and Threats 2025 (sbwire.com)
- Bone Growth Stimulator Market – Global Opportunity Analysis and Industry Forecast (2017-2022) (econotimes.com)
- Spine Biologics Market Report By Market data forecast (emailwire.com)
- Artificial Organs and Bionics Market Size, Share, Top Manufacturers, Suppliers, Demand, Regions, Revenue and 2023 Growth Forecast (medgadget.com)
A number of research firms have recently commented on OFIX. BidaskClub raised shares of Orthofix International from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. TheStreet cut shares of Orthofix International from a “b” rating to a “c+” rating in a research note on Tuesday, October 31st. BTIG Research set a $56.00 price objective on shares of Orthofix International and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, Zacks Investment Research raised shares of Orthofix International from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $54.42.
Shares of Orthofix International (OFIX) opened at $51.81 on Wednesday. Orthofix International has a one year low of $32.51 and a one year high of $54.73. The stock has a market cap of $963.51, a PE ratio of 34.54, a P/E/G ratio of 2.62 and a beta of 0.14.
Orthofix International (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, October 30th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.01. Orthofix International had a net margin of 0.33% and a return on equity of 10.26%. The company had revenue of $105.30 million during the quarter, compared to analysts’ expectations of $100.67 million. During the same quarter in the prior year, the company earned $0.36 EPS. Orthofix International’s revenue was up 6.9% compared to the same quarter last year. analysts predict that Orthofix International will post 1.61 earnings per share for the current year.
In other news, Director Luke T. Faulstick sold 4,800 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $51.22, for a total value of $245,856.00. Following the completion of the sale, the director now owns 7,729 shares of the company’s stock, valued at approximately $395,879.38. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Brad Mason sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total transaction of $267,400.00. Following the completion of the sale, the chief executive officer now directly owns 183,053 shares of the company’s stock, valued at approximately $9,789,674.44. The disclosure for this sale can be found here. 5.60% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Orthofix International (OFIX) Stock Price” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-orthofix-international-ofix-stock-price/1760389.html.
About Orthofix International
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.